The findings suggest that the interaction between acidocin A and ROR-1 may disrupt crucial signaling pathways involved in cancer cell survival, positioning it as a viable candidate for further preclinical and clinical development as an anticancer agent. This evidence concerns the gene ROR1 and cancer.